Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.

View in: PubMed

subject areas

Adult
Disease-Free Survival
Female
Follow-Up Studies
Fusion Proteins, bcr-abl
Gene Expression Regulation, Leukemic
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Protein Kinase Inhibitors
RNA, Messenger
RNA, Neoplasm
Survival Rate

authors with profiles

RAJYALAKSHMI LUTHRA
ZEEV ESTROV
ELIAS JOSEPH JABBOUR
GAUTAM BORTHAKUR
TAPAN MAHENDRA KADIA
NAVEEN PEMMARAJU
KEYUR PRAVINCHANDRA PATEL
NAVAL DAVER
RASHMI KANAGAL SHAMANNA
HAGOP M KANTARJIAN